Press releases

Key highlights

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

– 26 October 2023 – 1 mins read

26 October 2023 – 1 mins read

Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year guidance

Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today presents its sales performance for the year to date and the third quarter of 2023.

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– 21 August 2023 – 1 mins read

21 August 2023 – 1 mins read

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

– Cabozantinib in combination with atezolizumab demonstrated a statistically significant reduction in the risk of disease progression or death compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

– 16 August 2023 – 1 mins read

16 August 2023 – 1 mins read

US FDA approves Ipsen’s Sohonos™ (palovarotene) capsules, the first and only treatment for people with fibrodysplasia ossificans progressiva

PARIS, FRANCE, 16 August 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today approval by the U.S. Food and Drug Administration (FDA) of Sohonos™ (palovarotene) capsules as a retinoid indicated for the reduction in volume of new heterotopic ossification in…

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

– 27 July 2023 – 1 mins read

27 July 2023 – 1 mins read

Ipsen delivers solid H1 2023 results and upgrades its full-year guidance

The performance in the first half of the year is reflected in today’s upgrade to our full-year guidance. We look forward to more milestones and further expansion of the pipeline over time through additional external-innovation transactions. I am confident, as…

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

– 19 July 2023 – 1 mins read

19 July 2023 – 1 mins read

Ipsen announces European Commission decision on palovarotene for the treatment of FOP

PARIS, FRANCE, 19 July 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the European Commission has followed guidance provided by the Committee for Medicinal Products for Human Use (CHMP) in May this year, and has not granted marketing…